• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
  • Contact Us
Conservation of HIV-1 T cell epitopes across time and clades: Validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine

Conservation of HIV-1 T cell epitopes across time and clades: Validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine

by Adam | Oct 22, 2016

Vaccine. 2012 Dec 14;30(52):7547-60. PMCID: PMC3522424
H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance

H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance

by Adam | Oct 22, 2016

Immunogenicity of Teffector and Treg epitopes from H7N9 avian-origin influenza: Impact of cross-reactivity with the human genome

Immunogenicity of Teffector and Treg epitopes from H7N9 avian-origin influenza: Impact of cross-reactivity with the human genome

by Adam | Oct 22, 2016

Immunogenicity of Teffector and Treg epitopes from H7N9 avian-origin influenza: Impact of cross-reactivity with the human genome

Immunogenicity of Teffector and Treg epitopes from H7N9 avian-origin influenza: Impact of cross-reactivity with the human genome

by Adam | Oct 21, 2016

Recent Posts

  • Thinking Out Loud: September 2024
  • The Amsterdam Immunogenicity and Tolerance Seminar: 2024
  • The Computational Vaccinology Symposium: 2024
  • The Westin Immunogenicity Seminar: 2024
  • Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

Knowledge Base

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline